top of page
Profile
Join date: Jul 4, 2022
Posts (90)
Mar 13, 2026 ∙ 1 min
Preprint Study Examines Transcriptomic Effects of CNR-401 and Cannflavin A in an ALS Model
A newly released preprint from Canurta’s Bioinformatics team, with contributions from collaborators at Washington State University and the University of Guelph, explores how CNR-401 and Cannflavin A influence gene expression in a Drosophila model of amyotrophic lateral sclerosis (ALS).
9
0
Mar 2, 2026 ∙ 1 min
Preclinical Study Evaluates Cannflavins A and B in Glioblastoma Cell Models
A newly published peer-reviewed study, “Preclinical study of cannflavins A and B action against glioblastoma cells,” evaluates the biological activity of cannflavins A and B in laboratory models of glioblastoma multiforme (GBM)
22
0
Feb 17, 2026 ∙ 3 min
Canurta Therapeutics Partners with extractX to Integrate Proprietary Extraction Expertise into Enhanced Mobile Lab Platform
Canurta Therapeutics, a biotechnology company developing multi-target botanical therapeutics for complex inflammatory and neurological conditions, today announced a partnership with extractX Ltd. in connection with extractX’s enhanced Extraction Mobile Lab (EML 2.0) platform.
285
0
Canurta
Writer
More actions
bottom of page